TERT mutations are common in several types of cancer, including melanoma, glioblastoma, bladder cancer, and hepatocellular carcinoma. In melanoma, TERT promoter mutations are among the most frequent genetic alterations, indicating their significant role in the disease. In glioblastomas, these mutations are associated with poor prognosis and aggressive tumor growth. The presence of TERT mutations in bladder cancer is linked to poor survival rates, making it a critical focus for research and therapeutic targeting.
